NIH clinical trial testing antiviral remdesivir plus anti-inflammatory drug baricitinib for COVID-19 begins
National Institutes of Health (NIH) sent this bulletin at 05/08/2020 02:30 PM EDTHaving trouble viewing this email? View it as a Web page.
You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
05/08/2020 01:45 PM EDT
The trial is now enrolling hospitalized adults with COVID-19 in the United States.
Update Your E-mail Address | Add Subscriptions | Unsubscribe
If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website.
This service is provided to you by the National Institutes of Health.
NIH…Turning Discovery Into Health®
 |